All In Biotech

Drug Trial Radar · NCT00922779

A Study of Ribavirin in Combination With PEGASYS (Peginterferon Alfa-2a (40KD))in Patients With Chronic Hepatitis C

Safety and Tolerability of Ribavirin (RO 20-9963) in Combination With Peginterferon Alfa-2a (40 kD)in Patients With Chronic Hepatitis C

Last checked: Nov 20, 2026Latest source record: Jan 20, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

6,661

Actual

Start

Jun 2002

Primary completion

Jun 2012

Study completion Jun 2012

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Jun 17, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This single arm study will evaluate the safety and tolerability of ribavirin in combination with PEGASYS in patients with chronic hepatitis C. Patients will receive ribavirin 800mg, or 1000-1200mg po daily, according to HCV genotype and body weight (\< and \>75kg)in combination with PEGASYS 180micrograms sc weekly. The anticipated time on study treatment is 3-12 months, and the target sample size is \>500 individuals.

Conditions

  • Hepatitis C, Chronic

Interventions

  • peginterferon alfa-2a [Pegasys]Drug

    180micrograms sc weekly for 12-48 weeks

  • ribavirinDrug

    800mg, or 1000-1200mg, po daily (dependent on HCV genotype and body weight)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Non-Serious Adverse Events (AEs) And Serious Adverse Events (SAEs)Time frame: From signing of informed consent up to end of study (up to Week 72)

Locations

93 sites in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Arkhangelsk, Russia

  • Site not named

    Barnaul, Russia

  • Site not named

    Barnaul, Russia

  • Site not named

    Blagoveshchensk, Russia

  • Site not named

    Cheboksary, Russia

  • Site not named

    Chelyabinsk, Russia

  • Site not named

    Chelyabinsk, Russia

  • Site not named

    Chelyabinsk, Russia

  • Site not named

    Cherepovets, Russia

  • Site not named

    Chita, Russia

  • Site not named

    Irkutsk, Russia

  • Site not named

    Irkutsk, Russia

  • Site not named

    Irkutsk, Russia

  • Site not named

    Izhevsk, Russia

  • Site not named

    Kazan', Russia

  • Site not named

    Kemerovo, Russia

  • Site not named

    Kemerovo, Russia

  • Site not named

    Kemerovo, Russia

  • Site not named

    Khabarovsk, Russia

  • Site not named

    Khabarovsk, Russia

  • Site not named

    Khabarovsk, Russia

  • Site not named

    Kirov, Russia

  • Site not named

    Krasnodar, Russia

  • Site not named

    Krasnodar, Russia

  • Site not named

    Krasnodar, Russia

  • Site not named

    Krasnoyarsk, Russia

  • Site not named

    Krasnoyarsk, Russia

  • Site not named

    Lipetsk, Russia

  • Site not named

    Makhachkala, Russia

  • Site not named

    Moscow, Russia

  • Site not named

    Moscow, Russia

  • Site not named

    Moscow, Russia

  • Site not named

    Moscow, Russia

  • Site not named

    Moscow, Russia

  • Site not named

    Moscow, Russia

  • Site not named

    Moscow, Russia

  • Site not named

    Moscow, Russia

  • Site not named

    Moscow, Russia

  • Site not named

    Moscow, Russia

  • Site not named

    Moscow, Russia

Showing 40 of 93 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.